Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women diagnosed with a specific type of invasive breast cancer (called non-special type mammary carcinoma), across any of its main subtypes (luminal, triple-negative, or HER2-positive).
- People for whom doctors have recommended chemotherapy given before surgery (known as neoadjuvant chemotherapy).
- People who had a small marker clip placed into the tumor before starting pre-surgery chemotherapy.
- People whose cancer has been staged as a certain early-to-intermediate range (cT1–T3, N0–N1, M0), assessed through physical examination, mammogram, breast MRI, CT scan of the chest, abdomen and pelvis, and a bone scan.
- People who, after completing pre-surgery chemotherapy and before surgery, show either a complete response with no visible cancer remaining on scans, or a remaining tumor measuring 2 cm or less on mammogram and MRI.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose cancer appears in more than two separate locations in the breast (multicentric tumors).
- People currently taking blood-thinning medications (anticoagulants).
- People who have extensive calcium deposits in the breast area larger than 2 cm.
- People who are pregnant.
- People who are not planning to have surgery as part of their treatment.
- People who have had another cancer diagnosis within the last 5 years.
- People whose marker clip has moved away from the original tumor site and no remaining tumor can be seen on imaging in that area (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: José RM Piato, MD, PhD, Breast Surgeon at ICESP; Associate Professor at FMUSP.
Phone: 55 3893-2000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sensitivity, Specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV) of Vacuum-Assisted Biopsy (VAB) in Detecting Pathological Complete Response (pCR) Compared to Surgical Specimen Histopathology
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.